Golde Named Physician-in Chief at Memorial Hospital

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 23 No 5
Volume 23
Issue 5

NEW YORK--Dr. David W. Golde has been appointed Physician-in-Chief of Memorial Hospital, Dr. Paul Marks, president of Memorial Sloan-Kettering Cancer Center, announced. Dr. Golde succeeds Joseph V. Simone, MD, who is to become clinical director for the Huntsman Cancer Institute, Salt Lake City.

NEW YORK--Dr. David W. Golde has been appointed Physician-in-Chiefof Memorial Hospital, Dr. Paul Marks, president of Memorial Sloan-KetteringCancer Center, announced. Dr. Golde succeeds Joseph V. Simone,MD, who is to become clinical director for the Huntsman CancerInstitute, Salt Lake City.

Dr. Golde was head of the Cancer Center's Division of HematologicOncology, Department of Medicine, as well as head of the Laboratoryof Molecular and Cellular Hematology at the Sloan-Kettering Institute.He is renowned for his contributions to the understanding of normaland leukemic blood cell growth. His demonstration that certainwhite blood cells produce colony-stimulating factors in humanslaid the groundwork for the isolation of these factors.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content